Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2024 | |
|---|---|---|
| Revenue | $0 | $196.3M |
| Cost of revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Gross margin | — | 0.0% |
| R&D | $0 | $0 |
| Operating income | $296.8K | $29.6M |
| EBITDA | −$295.7K | $141.7M |
| Net income | −$295.7K | $17.8M |
| Net margin | — | 9.1% |
| EPS (diluted) | -0.01 | 0.01 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CBAH.
No tracked institution reports a position in CBAH as of their last filing.
No one on the platform has traded CBAH yet.
| $1.8B |
| — |
| GXIIGX Acquisition Corp. II | $6.69 | -10.44% | $280M | — |
| HLGNHeliogen, Inc. | $1.70 | +2.10% | $10M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.